ALNY
Price:
$278.09
Market Cap:
$37.13B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepati...[Read more]
Industry
Biotechnology
IPO Date
2004-06-01
Stock Exchange
NASDAQ
Ticker
ALNY
According to Alnylam Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 69.87. This represents a change of 1.08% compared to the average of 5.93 of the last 4 quarters.
The mean historical PE Ratio of Alnylam Pharmaceuticals, Inc. over the last ten years is -11.76. The current 69.87 PE Ratio has changed -59535.54% with respect to the historical average. Over the past ten years (40 quarters), ALNY's PE Ratio was at its highest in in the December 2025 quarter at 70.51. The PE Ratio was at its lowest in in the June 2024 quarter at -467.92.
Average
-11.76
Median
-20.43
Minimum
-107.94
Maximum
166.38
Discovering the peaks and valleys of Alnylam Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 199.90%
Maximum Annual PE Ratio = 166.38
Minimum Annual Increase = -254.14%
Minimum Annual PE Ratio = -107.94
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 166.38 | -254.14% |
| 2024 | -107.94 | 98.50% |
| 2023 | -54.38 | 112.80% |
| 2022 | -25.55 | 8.50% |
| 2021 | -23.55 | 35.19% |
| 2020 | -17.42 | 22.68% |
| 2019 | -14.20 | 47.44% |
| 2018 | -9.63 | -58.91% |
| 2017 | -23.44 | 199.90% |
| 2016 | -7.82 | -71.36% |
The current PE Ratio of Alnylam Pharmaceuticals, Inc. (ALNY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.35
5-year avg
-9.01
10-year avg
-11.76
Alnylam Pharmaceuticals, Inc.’s PE Ratio is greater than argenx SE (49.74), greater than Regeneron Pharmaceuticals, Inc. (14.34), greater than IDEXX Laboratories, Inc. (41.12), greater than Becton, Dickinson and Company (36.45), greater than Zoetis Inc. (12.57), greater than Edwards Lifesciences Corporation (46.22), greater than Cencora, Inc. (20.72), greater than Veeva Systems Inc. (26.61), greater than Cigna Corporation (11.77), greater than Cardinal Health, Inc. (33.81),
| Company | PE Ratio | Market cap |
|---|---|---|
| 49.74 | $54.32B | |
| 14.34 | $62.84B | |
| 41.12 | $44.34B | |
| 36.45 | $52.16B | |
| 12.57 | $33.00B | |
| 46.22 | $50.30B | |
| 20.72 | $52.89B | |
| 26.61 | $24.90B | |
| 11.77 | $73.88B | |
| 33.81 | $51.94B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alnylam Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Alnylam Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Alnylam Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Alnylam Pharmaceuticals, Inc. (ALNY)?
What is the highest PE Ratio for Alnylam Pharmaceuticals, Inc. (ALNY)?
What is the 3-year average PE Ratio for Alnylam Pharmaceuticals, Inc. (ALNY)?
What is the 5-year average PE Ratio for Alnylam Pharmaceuticals, Inc. (ALNY)?
How does the current PE Ratio for Alnylam Pharmaceuticals, Inc. (ALNY) compare to its historical average?